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Abstract
Enzymes catalysing the methylation of the 5-position of cytosine (mC) have essential roles in
regulating gene expression and maintaining cellular identity. Recently, TET1 was found to
hydroxylate the methyl group of mC, converting it to 5-hydroxymethyl cytosine (hmC). Here we
show that TET1 binds throughout the genome of embryonic stem cells, with the majority of
binding sites located at transcription start sites (TSSs) of CpG-rich promoters and within genes.
The hmC modification is found in gene bodies and in contrast to mC is also enriched at CpG-rich
TSSs. We provide evidence further that TET1 has a role in transcriptional repression. TET1 binds
a significant proportion of Polycomb group target genes. Furthermore, TET1 associates and
colocalizes with the SIN3A co-repressor complex. We propose that TET1 fine-tunes transcription,
opposes aberrant DNA methylation at CpG-rich sequences and thereby contributes to the
regulation of DNA methylation fidelity.
Introduction
The majority of CpGs in mammalian genomes are methylated. An exception to this is CpG
islands, which are found in more than 60% of all mammalian gene promoters. These are
often unmethylated and can be either transcriptionally active or inactive depending on other
factors, including histone modifications and the activity of cell-type-specific transcription
factors1, 2, 3, 4, 5. In current models for gene regulation, CpG methylation in promoters
leads to stable gene silencing, whereas the function of intragenic methylation might, like
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trimethylation of histone 3 lysine 36 (H3K36me3), repress the initiation of intragenic
transcription6.
DNA methyltransferases are essential for embryogenesis, and the methylation pattern of the
mammalian genome undergoes major changes during development. As an example, global
waves of DNA demethylation and remethylation take place after fertilization, and gene-
specific de novo methylation occurs during differentiation of embryonic stem (ES) cells6, 7.
Importantly, patterns of DNA methylation are perturbed in human diseases such as
imprinting disorders and cancer8. So far there is very limited knowledge regarding the
mechanisms leading to DNA hypermethylation of CpG-island promoters in cancer, and how
CpG-islands generally remain unmethylated in somatic cells.
Enzymes contributing to DNA demethylation could potentially provide a fidelity system for
DNA methylation, but such enzymes were not known until recently. In a ground-breaking
paper, TET1 was shown to catalyse the hydroxylation of mC9, which has led to the proposal
of several models for how TET1 and hmC may contribute to DNA demethylation and gene
regulation. One possibility is that hydroxylation of mC by TET1 might interfere with
DNMT1 activity, leading to a subsequent passive loss of methylation following replication.
Alternatively, hmC may be converted to cytosine through hitherto unknown enzymatic
mechanisms. In addition, hydroxylation of mC may promote transcriptional de-repression by
dissociation of mC-binding proteins and/or recruitment of effector proteins. The
demonstration that hmC is highly abundant in ES cells and in neuronal Purkinje cells
indicates that this modification is stably present in the mammalian genome and that it might
be important for gene regulation9, 10.
TET1 binds CpG-rich transcription start sites
TET1 is highly expressed in mouse ES cells and is rapidly downregulated during their
differentiation9, 11. To obtain more information regarding the function of TET1, we
inhibited TET1 expression in mouse ES cells using two different shRNA constructs (Fig. 1a
and Supplementary Fig. 1a). The efficient knockdown of Tet1 did not lead to any change in
proliferation rate or expression of NANOG and OCT4 (Fig. 1a and Supplementary Fig. 1a,
b). These data are in agreement with a recently published study12, but in contrast to results
reported by others13. We also observed inhibition of growth and decreased levels of
NANOG in mouse ES cells when using the Tet1 shRNA sequences published in the latter
study (Supplementary Fig. 1c, d). However, as these shRNA sequences do not lead to
greater knockdown efficiency than the ones we have used (Supplementary Fig. 1c), it is
possible that shRNA off-target effects could cause the observed phenotype.
We determined the genome-wide location of TET1 by using two different antibodies to
TET1 (Tet1-N and Tet1-C) for chromatin immunoprecipitation followed by DNA
sequencing (ChIP-seq). These experiments were performed in control or TET1-depleted
mouse ES cells. The two TET1 antibodies were highly specific as shown in the examples
provided in Fig. 1b and by the fact that 97–99% of the identified TET1 binding sites were
not found in the TET1-depleted cells (Supplementary Fig. 2a). The majority of TET1
binding sites were found in gene bodies, with the highest density around TSSs (Fig. 1c).
Gene annotation of TET1 binding sites, using a false discovery rate (FDR) < 0.01, showed
that TET1 binds in the vicinity of the TSS of 6,573 genes (Fig. 1d and Supplementary Table
1), of which all tested so far have been independently validated by ChIP followed by real-
time quantitative PCR (ChIP-qPCR, Supplementary Fig. 2b and data not shown). Peak
detection analysis using FDR < 0.1 indicates that TET1 could have up to 9,241 target genes
(Supplementary Fig. 3a). Gene Ontology analysis showed that TET1 target genes are
involved in a variety of basic cellular processes, and in more specific processes such as
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development and differentiation (Supplementary Fig. 3b). The majority of the TET1 target
genes are associated with high and intermediate density CpG promoters (HCPs and ICPs,
Fig. 1e), which are positive for H3K4me3 (Fig. 1f). The correlation between TET1 binding
and high CpG density is also found outside of TSSs (Supplementary Fig. 4). Interestingly,
TET1 binding does not predict whether a promoter is active, poised for activation (non-
productive) or inactive (Fig. 1g). In agreement with this, we found that a significant fraction
of TET1 was associated with promoters containing the H3K27me3 Polycomb repressive
mark (Fig. 1f). Indeed, independent analysis showed a highly significant overlap of genes
bound by TET1 and the Polycomb group (PcG) protein, SUZ12, in ES cells (Supplementary
Fig. 5a, b).
hmC is enriched at TSSs and gene bodies
To gain information regarding a possible function of hmC, we generated an affinity-purified
polyclonal antibody to hmC that binds with high specificity and sensitivity to this mark, as
shown by enzyme-linked immunosorbent (ELISA) and DNA immunoprecipitation (DIP)
assays (Supplementary Fig. 6). Genome-wide DIP-seq assays were performed using anti-
hmC, anti-mC and IgG on genomic DNA purified from control or TET1-depleted ES cells
as well as from Dnmt triple knockout (TKO) mouse ES cells, lacking Dnmt1, Dnmt3a and
Dnmt3b14. We confirmed by ChIP-qPCR that TET1 localizes to its target genes in the Dnmt
TKO cells (Supplementary Fig. 7a). The analyses showed that hmC is located as discrete
peaks throughout the genome (Fig. 2a). Furthermore, the majority of signals obtained with
the hmC antibody were absent in Dnmt TKO mouse ES cells, confirming that generation of
hmC requires the pre-existence of mC (Fig. 2a). The hmC modification in mouse ES cells is
particularly enriched within gene bodies as also observed for the mC mark15 and recently
reported for hmC in mouse cerebellum16 (Fig. 2b, c). Strikingly, in contrast to the
localization of mC, hmC is also significantly enriched at the TSS coinciding with TET1
(Fig. 2c), indicating that a significant fraction of mC is converted to hmC at the TSS. Also,
the hmC modification is generally not detectable at repetitive elements such as intracisternal
A particle (IAP) elements and minor satellite repeats by DIP-qPCR (Supplementary Fig.
7b), further demonstrating that hmC and mC show distinct genomic distributions.
Gene annotation of hmC positive regions around the TSS (−0.7 kilobases to +0.3 kb)
showed that 2,424 regions are hmC-positive in wild-type ES cells compared to Dnmt TKO
ES cells. Approximately 28% of these regions showed a more than twofold reduction in
hmC signal in the DIP-seq analyses upon downregulation of TET1 (Fig. 2d) and in
validation experiments the knockdown of Tet1 led to a significant decrease in hmC levels on
tested genes (Fig. 2e and data not shown). Depending on the used false discovery rate cut-
off for TET1, between 35% (FDR < 0.01) and 50% (FDR < 0.1) of hmC-positive genes are
bound by TET1 (Fig. 2f). These results are in agreement with reports showing that Tet1
knockdown only causes a partial decrease in global hmC levels in mouse ES cells9, 12, and
imply that, although TET1 is important for the generation of hmC, other enzymes such as
TET2 are also likely to contribute to hmC levels in mouse ES cells.
As for TET1, Gene Ontology analysis of the hmC-positive genes showed enrichment for
genes involved in basic cellular processes, but also in the regulation of development and
differentiation (Supplementary Fig. 7c). Moreover, hmC positivity does not correlate with
transcriptional activation and surprisingly, most hmC-positive genes seem not to be
expressed in mouse ES cells (Fig. 2g).
A significant proportion of the TSSs classified as positive for hmC has intermediate or high
CpG content (Fig. 2h and Supplementary Fig. 4). Genome-wide analyses of the hmC
distribution relative to CpG content showed that the hmC mark is enriched in regions with
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relatively high CpG content compared to mC (Fig. 2i). Whereas only 15% of hmC-positive
TSSs also contain a high mC signal, we find that several hmC-positive regions have low
levels of mC, implying that the two marks often co-exist. Upon Tet1 knockdown only a
minor global increase in mC was observed as evaluated by genome-wide anti-mC DIP (Me-
DIP) (Supplementary Fig. 8a). However, a few hundred genes show modest TSS specific
increases in mC levels after Tet1 knockdown (Supplementary Fig. 8b). Gene Ontology
analyses for these genes showed enrichments for specialized developmental processes
(Supplementary Fig. 8c). Interestingly, we found that approximately a third of the genes
reported to acquire DNA methylation during ES cell differentiation2, 3 are marked by hmC
in the ES cell state (Supplementary Table 2). Taken together, these results show that hmC
colocalizes with mC in gene-bodies, and that hmC, in contrast to mC, is enriched at TSSs
with intermediate to high CpG density, where it may contribute to the regulation of DNA
methylation patterns.
TET1 contributes to transcriptional repression
To understand how TET1 contributes to the regulation of target genes, we performed
genome-wide expression analyses of mouse ES cells expressing two different Tet1 shRNAs
or a scrambled shRNA (Supplementary Fig. 9a, b and Supplementary Table 3). As shown in
Fig. 3a and Supplementary Fig. 9c, we observed a significant decrease in expression of 556
genes and a significant increase in expression of 851 genes common to both shRNAs. Of
these approximately 700 were direct target genes of TET1, and therefore only around 10%
of all TET1 target genes change expression following Tet1 knockdown. Whereas we
expected to observe a significant fraction of the downregulated genes to be direct targets for
TET1, we were surprised to find that an even higher fraction of the upregulated genes were
associated with TET1 (Fig. 3a). To validate these results, we performed qPCR analysis of a
number of downregulated and upregulated genes (Fig. 3b) that were also directly bound by
TET1 (Supplementary Fig. 2b). Moreover, several of the identified targets show similar
expression change upon differentiation of mouse ES cells by retinoic acid, which leads to
decreased levels of TET1 (Supplementary Fig. 9d).
To investigate whether the transcriptional effects of TET1 are mediated by modulating hmC
and mC levels, we performed knockdown of Tet1 in Dnmt TKO cells (Supplementary Fig.
10a). We found that all the tested transcriptional effects by knockdown of Tet1 were similar
in Dnmt TKO and normal ES cells (Fig. 3c and Supplementary Fig. 10b), indicating that the
effects are independent of catalytic activity. However, we cannot rule out that TET1-
dependent modulation of hmC and mC might contribute to transcriptional fine-tuning at
some target genes. Taken together, these results indicate that TET1 can contribute to
transcriptional repression, and to a minor extent also transcriptional activation, and that the
majority of TET1-mediated transcriptional effects are independent of conversion of mC to
hmC.
TET1 associates with the SIN3A complex
The mechanism by which TET1 contributes to transcriptional repression is unknown.
Although we find an extensive overlap between TET1 and PcG target genes, we have not
been able to detect a physical interaction of TET1 with PcG proteins. Therefore, we purified
proteins associated with double-epitope Flag–haemagglutinin (Flag–HA)-tagged TET1
expressed in HEK293 cells. This purification led to the identification of SIN3A and several
other core components of the SIN3A co-repressor complex, which we did not find
associated with the TET2 hydroxylase (Fig. 4a). The SIN3A co-repressor complex is
thought to contribute to transcriptional repression by mediating histone deacetylation17. We
validated the interaction between SIN3A and TET1 in vivo by co-immunoprecipitation of
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endogenous proteins with and without the DNA intercalating agent ethidium bromide (Fig.
4b and Supplementary Fig. 11a). Furthermore, TET1 expressed as a fusion protein with the
GAL4 DNA binding domain was sufficient to recruit SIN3A to the GAL4 DNA binding
sites in vivo (Supplementary Fig. 11b–e).
To understand if SIN3A also colocalizes with TET1 on target genes, we performed ChIP-
seq analysis using two different commercial antibodies to SIN3A (Fig. 4c, Supplementary
Table 1). This analysis showed that SIN3A has a similar binding profile as TET1 (Fig. 4d, e
and Supplementary Fig. 4), and that TET1 and SIN3A display a significant overlap of target
genes (Fig. 4f and Supplementary Fig. 12a). Moreover, ChIP experiments showed that TET1
contributes significantly to the recruitment of SIN3A (Fig. 4g), whereas depletion of SIN3A
had no or modest effect on TET1 binding to tested target genes (Supplementary Fig. 12b).
To understand if SIN3A is required for the silencing of TET1 repressed genes, we
performed gene expression analysis of Sin3A knockdown cells (Supplementary Fig. 12c and
Supplementary Table 4). Here we found an extensive overlap between genes with increased
expression after Tet1 and Sin3A knockdown that are also directly bound by both TET1 and
SIN3A (Supplementary Fig. 12d). This implies that SIN3A is required for the repression of
a subset of TET1 target genes that show increased expression upon TET1 downregulation
(Fig. 4h).
Discussion
One of the major findings presented in this paper is that TET1 localizes to gene bodies and
TSSs of a large number of genes and is particularly enriched on genes with high CpG-
content. In contrast to the global pattern of mC, which is found predominantly in low CpG
density regions, we found that hmC colocalizes with TET1 at high and intermediate CpG-
content sequences. This finding indicates that TET1 could have an important role in the
metabolism of mC at CpG-rich sequences by converting it to hmC. Statistically significant
hmC levels were not detected around the TSS at the majority of TET1 target genes. It is
possible that these genes are not methylated and therefore cannot be subsequently
hydroxymethylated. Alternatively, it is tempting to speculate that low and stochastically
placed methylations on these CpG-rich genes are passively eliminated through replication in
rapidly dividing ES cells, following TET1-mediated hydroxylation. If so, the generated hmC
will most likely not be detected by DIP-analyses because it will only occur in few cells in
the total cell population. In this way the role of TET1 would be to remove aberrant
stochastic DNA methylation and contribute to regulating DNA methylation fidelity in ES
cells. However, we also found a large number of hmC-positive genes and, interestingly,
many of these become hypermethylated in differentiated cells, for example, Dazl, Hormad1,
Sycp1 and Sycp2 (ref. 2; Supplementary Table 2 and data not shown). This suggests a dual
biological role of TET1, one in which it removes aberrant DNA methylation and another
that ensures the timely DNA methylation and silencing of target genes during
differentiation.
We also provide evidence that TET1 has a role in transcriptional repression. Interestingly,
downregulation of TET1 in Dnmt TKO ES cells leads to upregulation of the same genes as
observed in wild-type ES cells, indicating that the repressive function of TET1 is
independent of its catalytic activity. We found that TET1 interacts with the SIN3A complex
and the extensive colocalization of TET1 and the SIN3A co-repressor complex at target
genes suggests that SIN3A has an important function in TET1-mediated gene repression.
In summary, our results indicate that TET1 is required for the timely expression of genes
during development. We propose that TET1 by converting mC to hmC serves an important
function in the regulation of DNA methylation fidelity. In turn this conversion may lead to a
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reduction of DNA methylation at CpG-rich gene regulatory sequences. Thus, loss of
function of the TET proteins would promote the stochastic hypermethylation of promoters
leading to deregulation of transcription and differentiation. Interestingly, the related TET2
oxygenase is frequently mutated in a variety of haematopoietic neoplasms supporting an
important role of conversion of mC to hmC in cellular homeostasis 18, 19.
Methods
Cell culture
Low passage (p17) E14TG2a.4 feeder independent ES cells were grown on 0.1% gelatin-
coated plates in Glasgow medium (Sigma) supplemented with glutamine (Gibco),
nonessential amino acids (Gibco), sodium pyruvate (Gibco), 50 μM β-mercaptoethanol, and
15% fetal bovine serum (HyClone) in the presence of leukaemia inhibitory factor (LIF).
Recombinant lentiviruses encoding Tet1 and Sin3A shRNA were produced by standard
methods employing co-transfection of pLKO.1 shRNA and packaging vectors in 293FT
cells. shRNA-transduced ES cells were selected 36 h post transduction with 2 μg per ml of
puromycin for 72 h. For Sin3A knockdown, cells were harvested after 48 h to minimize
differentiation. Tet1 shRNAs had the following sequences, shTet1#3: 5′-
tgtagaccatcactgttcgac-3′, shTet1#4: 5′-tcatctacttctcacctagtg-3′, shTet1#5: 5′-
agagaacctggtgcatcagat-3′, shTet1#A: 5′-gcagatggccgtgacacaaat-3′ and shTet1#B: 5-
gctcatggagactaggtttgg-3′. Sin3A shRNA had the following sequence, shSin3A#73: 5′-
gctgttccgattgtccttaaa-3′.
Cloning procedures
The open-reading frames (ORF) of mouse Tet1 and Tet2 were amplified by PCR using
cDNA from mouse ES cells or LPS-stimulated RAW264.7 mouse macrophages as template,
respectively. The amplified fragments were cloned into the pCR8/GW gateway entry vector
(Invitrogen), and the DNA sequence was verified by sequencing. Coding errors according to
the GenBank reference sequences of mouse Tet1 and Tet2 were corrected by site-directed
mutagenesis. To generate expression vectors, the appropriate entry clones were transferred
into gateway-compatible pCDNA5 TO Flag–HA. shRNA constructs targeting Tet1 were
constructed in pLKO.1. shRNAs targeting murine Sin3A were obtained from Sigma-
Aldrich.
Generation of antibodies to mouse TET1 and hydroxymethylcytosine
Polyclonal antibodies were generated by immunizing rabbits with affinity-purified
bacterially expressed GST–Tet1-N (amino acids 1–308) and GST–Tet1-C (amino acids
1739–2039). The antibodies were absorbed on GST-coupled cyanogen bromide-activated
Sepharose (GE Healthcare) and subsequently affinity purified using Sepharose coupled with
GST–Tet1-N or GST–Tet1-C. Antibody specificity was confirmed by immunoblotting and
immunoprecipitation. To generate antibodies against hydroxymethylcytosine, 5-
hydroxymethylcytidine (Berry & Associates), was covalently coupled to BSA essentially as
described28 and used for immunization of rabbits. Affinity-purified anti-
hydroxymethylcytosine (hmC) antibodies were produced by column absorption of the rabbit
antisera on methylcytidine-ovalbumin coupled to cyanogen bromide-activated Sepharose
followed by column-affinity purification on hydroxymethylcytidine-ovalbumin coupled to
Sepharose. The antibodies were eluted with 0.1 M glycine-HCl, neutralised, dialysed against
PBS and stored at −80 °C. The specificity of the purified anti-hmC antibodies were analysed
by ELISA and in hme-DIP assays. For the hme-DIP assays, synthetic 300-base-pair probes
incorporating 5, 20 and 100% hmC or mC, respectively, were amplified by PCR using
pCR8/GW (nucleotides 701–1000) as template. The probes (0.001 ng) were spiked into the
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hmeC/meC reactions containing 1 μg of sonicated ES DNA. Antibody reactivity with the
probes was detected by qPCR.
Purification of TET1 and TET2 complexes
To isolate TET1 and TET2-containing complexes, two-step affinity purification was
performed followed by mass spectrometry analysis. Nuclear extracts (250–500 mg, 3 × 109
cells) from Flp-In-T-REx-293 cell lines expressing Flag–HA-tagged murine TET1 or TET2
were precleared and incubated with a 700 μl packed volume of anti-Flag beads (anti-Flag
M2-agarose, Sigma) overnight at 4 °C with rotation. The beads were collected by
centrifugation at 700g for 5 min and washed six times with 40× resin bed volume of buffer
A (20 mM Tris-HCl, pH 8.0, 300 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 10% glycerol,
0.2 mM PMSF, 1 mM DTT, 1 μg ml–1 aproVnin and 1 μg ml–1 leupepVn). The beads were
transferred into a 10-ml poly-prep chromatography column (Bio-Rad) and complexes were
then eluted five times after 10 min of incubation using one resin bed volume of buffer A
supplemented with 0.5 μg μl–1 Flag pepVde. The eluate was subjected to a second round of
purification using an antibody against the HA-tag. The Flag-IP elute was incubated with 200
μl of a 50% slurry of HA-beads overnight. The beads were washed four times with buffer A
and eluted with 100 μl buffer A supplemented with 1 μg μl–1 HA pepVde for 2 h. The
samples were boiled in SDS loading buffer and run shortly into a SDS–PAGE gel in order to
remove the Flag and HA peptide and other contaminations. A gel slice containing the
purified proteins was isolated for mass spectrometry analysis.
ChIP/DIP assays and ChIP/DIP-seq
Chromatin immunoprecipitation assays (ChIP) were performed and analysed as previously
described21. The antibodies used were anti-mSin3A (Abcam AB3479, Santa Cruz sc-994X)
and the antibodies to TET1 described above. ES cell DNA was sonicated to an average size
between 300 and 600 bp. Adaptor-ligated libraries for hmC or mC DNA
immunoprecipitations assays (hm-DIP/me-DIP) were constructed using the NEBNext DNA
Sample Prep Master Mix, NEB combined with Illumina adaptors. hme/me-DIP assays were
performed as described22 using 1 μg of denatured sonicated or adaptor-ligated DNA in 100
μl of binding buffer and 0.1–4 μg of affinity-purified rabbit hmC antibody or monoclonal
mC antibody (Eurogentec BI-MECY-0500). The samples were incubated for four hours at 4
°C before addition of 10 μl of anti-rabbit/mouse Dynabeads (Invitrogen). After 2 h of
incubation, the samples were washed four times and bound DNA was eluted by incubation
for one hour at 55 °C in 100 μl of 50 mM Tris-HCl, 10 mM EDTA, 0.5% SDS and 20 μg
proteinase K. The DNA was purified using a QIAquick PCR purification kit (Qiagen) and
amplified by 16 cycles of PCR. For the MeCAP (methylated DNA capture by affinity
purification) experiments, the MethylCap kit (Diagenode) was used according to
manufacturer’s instructions. For ChIP-seq analysis, the DNA obtained from the ChIP assays
were adaptor-ligated and amplified using a kit from Illumina (IP-102-1001). The amplified
DNA from hme/me-DIP or ChIP-seq experiments was analysed by Solexa/Illumina high-
throughput sequencing. After prefiltering the raw data by removing sequenced adapters and
low quality reads, the tags were mapped to the mouse genome (assembly mm9) with the
Bowtie alignment tool. To avoid any PCR bias we allowed only one read per chromosomal
position (unless otherwise specified) thus eliminating spurious spikes. Peak detection were
performed in the CisGenome program23 at an FDR cut-off value <0.1 or <0.01 as indicated
in the text. IgG was used as control for normalization. Venn diagram analysis was
performed with Galaxy browser (www.galaxy.psu.edu). Most standard peak detection
programs are typically optimized for transcription binding site data and anticipate a defined
narrow bell-shaped density profile. However, for epigenetics data, such as mC and hmC, the
peaks tends to be broad and low-intensity, thus requiring a different peak detection program.
We used the MEDIPS tool24 (bin size = 50, fragment length = 250, frame size = 500, step =
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250) to detect significant enrichment of signal (reads per million, rpm) relative to a control
(Dnmt TKO DIP) and an input (IgG DIP) sample at an FDR cut-off value <0.1 and a
minimal enrichment of ratio >5. For the MEDIPS analysis the reads were not limited to one
read per chromosomal position, and the total length of the mapped reads were extended in
the direction of the 3′-end to a total length of 250 bases, which was our estimate of the mean
fragment length. Chromosomal positions (peaks) were annotated to the RefSeq database
(mm9) using the UCSC “refFlat” table29. Genes not uniquely mapped to the genome were
excluded. Signal vs CpG plot: for the signal vs CpG plots the MEDIPS calculated rpm and
CpG (CpG values from transformed “coupling” factors) values were used. To avoid
redundancy only the longest transcript variant of each gene was used to define chromosomal
locations of promoter, TSS, exons and introns. For each bin (non-overlapping) MEDIPS
determines the number of overlapping reads and the CpG content. For a specified region of
interest (ROI), for example, an exon, the mean rpm and CpG content of the bins within the
range was calculated. The distribution of CpG content within the different genomic
categories are distinctly different for example, with the TSS region showing the known
bimodal distribution. To depict the rpm as a function of CpG-content, the mean rpm values
were stratified according to CpG-content (1% resolution) and the mean of the mean rpms
within each stratus calculated. Due to variability in the size of ROIs (except for the genome-
wide analysis), the plots for the different genomic categories are not directly comparable.
Wiggle-based plots: to avoid redundancy, the longest transcript variant of each gene in the
RefSeq database was used as reference. In total the chromosomal mappings of 21,513
unique genes were used. The filtered alignment files were converted to bigWig files from
which the tag count information was extracted using unix tools from the UCSC website.
Gene Body plots: 40 non-overlapping windows with average tag number per base were
calculated for each gene. 10 kb upstream of TSS and 10 kb downstream of transcription end
site (TES) was divided into of windows of size 1 kb. Between TSS and TES each gene were
divided into 20 windows of equal (gene-specific) size and the average counts was
calculated. All statistics and plotting were done using the statistical program R.
mRNA expression analysis
For expression analysis, total RNA was purified from murine embryonic stem cells using
RNeasy (Qiagen). The RNA was reverse transcribed using TaqMan reverse transcription
reagents from ABI, according to the manufacturer’s instructions. For RNA quantification,
reversed-transcribed total RNA was analysed by real-time PCR using SYBR Green PCR
Master Mix (Fermentas) and an ABI prism 7700 Sequence Detection system. All reactions
were analysed in triplicates. Primer sequences are listed in Supplementary Figure 13 and
Supplementary Fig. 14. For microarray analysis, RNA was extracted with the RNeasy Plus
RNA extraction kit (Qiagen). RNA was hybridized on mouse Gene 1.0 ST arrays by the RH
Microarray Center at Rigshospitalet, Copenhagen, following Affymetrix procedures and
analysis. Gene expression analyses of RNA from shScr, shTet1#4, shTet1#5 and
shSin3A#73 cells were performed in triplicates and in the subsequent data analysis FDR
values <0.05 was used.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Identification of TET1 target genes.
a, Western blot showing TET1, OCT4 and NANOG levels for control-transfected (shScr)
and TET1-depleted (shTet1#3 and shTet1#5) mouse ES cells. b, Examples of TET1 ChIP-
seq results in control or Tet1 knockdown ES cells. ChIP-seq was performed using both an
anti-N- and anti-C-terminal TET1 antibody (Tet1-N and Tet1-C). y-axis of binding profiles
denotes number of sequence tag reads. c, Left panel, mean distribution of tags across gene
bodies for TET1 ChIP-seq in control and TET1 knockdown cells. Right panel, diagram
illustrating the overall distribution of TET1 binding sites into TSS (±1 kb), promoter (−1 to
−5 kb), exon, intron and intergenic regions. d, Venn diagram illustra5ng the overlap of
TET1 target genes using anti-TET1-N and -C antibodies. e, f, Histograms showing promoter
CpG density, divided into high-, intermediate- or low-density CpG promoters (HCP, ICP or
LCP) as defined in ref. 25 (e) or distribution of H3K4me3 (K4) and H3K27me3 (K27)25 (f)
for all genes or for TET1 target genes. g, Overlay of TET1 target genes with active genes
(RNA polymerase II binding and H3K79me2), non-productive (RNA polymerase II binding,
no H3K79me2) and inactive (no RNA polymerase II binding or H3K79me2)26, 27.
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Figure 2.
Hydroxymethylcytosine localizes to TSS and gene body.
a, Examples of hmC DIP-seq results in mouse ES cells. ChIP-seq profiles of TET1 are
included for comparison. b, Diagram illustrating the overall distribution of hmC into TSS
(±1 kb), promoter (−1 to −5 kb), exon, intron and intergenic regions. c, The mean
distribu5on of tags across gene bodies for hmC, mC and IgG. d, Almost a third (28%) of
hmC positive TSSs showed a more than twofold reduction in hmC signal in mouse ES cells
depleted of TET1. e, DIP-qPCR was performed in control mouse ES cells, Tet1 knockdown
cells (shTet1#3 and shTet1#5), and Dnmt TKO cells as indicated. f, Overlay of genes
positive for hmC at the TSS with TET1 target genes using FDR cut-off values of 0.01 or 0.1
in the ChIP-seq analysis. g, Overlay of hmC positive genes with active genes (RNA
polymerase II binding and H3K79me2), non-productive (RNA polymerase II binding, no
H3K79me2) and inactive (no RNA polymerase II binding or H3K79me2)26, 27. h,
Distribution of high-, intermediate- or low density CpG promoters (HCP, ICP or LCP)25 for
all genes or hmC-positive genes. i, Plot illustrating the genome-wide correlation of TET1,
hmC and mC signal intensity (rpm, reads per million) with CpG density. All error bars
denote s.d., n = 3.
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Figure 3.
Knockdown of Tet1 in ES cells affects transcription.
a, Microarray analyses were performed in control (shScr) and Tet1 knockdown cells
(shTet1#4 and shTet1#5) in triplicates. Venn diagram showing overlap between TET1-
bound genes, and genes up- or downregulated by both shRNAs using a cut-off of FDR <
0.05. b, qRT–PCR validation of selected genes. c, Genes that were found upregulated or
downregulated by Tet1 knockdown show similar regulation in Dnmt TKO ES cells. All
error bars denote s.d., n = 3.
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Figure 4.
TET1 interacts with SIN3A.
a, Peptides identified by mass spectrometry from anti-Flag and tandem anti-Flag–HA
purification of Flag–HA–TET1 and Flag–HA–TET2 stably expressed in 293 cells. The
presented proteins are all part of the SIN3A complex17. b, Antibodies specific for TET1,
SIN3A and c-Myc (negative control) were used for immunoprecipitation (IP) and western
blot (WB) using nuclear extracts from mouse ES cells. Input represents 8%. c, Examples of
SIN3A and TET1 ChIP-seq results in mouse ES cells. d, Diagram illustrating the overall
distribution of SIN3A binding sites into TSS (±1 kb), promoter (−1 to −5 kb), exon, intron
and intergenic regions. e, Mean distribution of tags across gene bodies for SIN3A and TET1.
f, Venn diagram illustrating a significant (P < 10–8) overlap between TET1 and SIN3A
target genes (FDR < 0.01). g, ChIP-qPCR in control or Tet1 knockdown cells (shTet1#4 and
shTet1#5). h, Left panel, western blot illustrating knockdown efficiencies of TET1 and
SIN3A. Right panel, genes that are upregulated by Tet1 knockdown are also de-repressed by
Sin3a knockdown. All error bars denote s.d., n = 3.
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